Lockwood, C M <br/><br/>
Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Dec 2003 
 - 1539-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1462-0324 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/keg424  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--adverse effects<br/>Antirheumatic Agents--adverse effects<br/>Behcet Syndrome--drug therapy<br/>CD4 Lymphocyte Count<br/>Disease-Free Survival<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Lymphocyte Depletion--methods<br/>Male<br/>Middle Aged<br/>Prednisolone--administration & dosage<br/>Remission Induction<br/>Treatment Outcome